Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA Combined With CIK Cells for Cholangiocarcinoma
NCT02482454Phase 3Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jul 2012
- Primary completion
- Jul 2030
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of unmodified CIK in cholangiocarcinoma (CCA), sponsored by Changzhou First People's Hospital. Primary endpoint: Recurrence-free survival at 1 year. Started Jul 2012; status: active, not recruiting.
02
Drugs
unmodified CIK
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02482454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482454.